Australian Auto Components Stock News

In recent months, TPG Telecom has faced intense regulatory scrutiny and a Senate inquiry in Australia after multiple Triple Zero (000) emergency call failures involving outdated Samsung devices on its network, with the company working with authorities to investigate possible links to customer deaths and urging tens of thousands of affected users to update their software or replace handsets. At the same time, TPG completed a retail reinvestment plan that raised A$73.40 million to repay bank...

Key Insights Autosports Group's estimated fair value is AU$6.19 based on 2 Stage Free Cash Flow to Equity Autosports...

The Cogstate Limited ( ASX:CGS ) share price has softened a substantial 27% over the previous 30 days, handing back...

From what we can see, insiders were net sellers in BlueScope Steel Limited's ( ASX:BSL ) during the past 12 months...

The Australian stock market has faced challenges recently, with the ASX200 underperforming compared to its global peers despite a US Fed Rate Cut. In such conditions, investors often look towards penny stocks as a potential avenue for growth. Although the term "penny stocks" may seem outdated, these smaller or newer companies can offer opportunities when they possess strong financials and clear growth prospects.

Greenhy2 Limited ( ASX:H2G ) insiders who bought shares over the past year were rewarded handsomely last week. The...

Key Insights Using the 2 Stage Free Cash Flow to Equity, NRW Holdings fair value estimate is AU$8.94 Current share...

With its stock down 16% over the past three months, it is easy to disregard Objective (ASX:OCL). But if you pay close...

Hazer Group Limited ( ASX:HZR ) shareholders should be happy to see the share price up 12% in the last quarter. But...

SGH Limited ( ASX:SGH ) received a lot of attention from a substantial price movement on the ASX over the last few...

With a price-to-sales (or "P/S") ratio of 3.3x Raiz Invest Limited ( ASX:RZI ) may be sending very bullish signals at...

When close to half the companies operating in the Consumer Services industry in Australia have price-to-sales ratios...

We wouldn't blame Catalyst Metals Limited ( ASX:CYL ) shareholders if they were a little worried about the fact that...

Most readers would already be aware that Whitehaven Coal's (ASX:WHC) stock increased significantly by 21% over the past...

Key Insights Tesoro Gold's significant individual investors ownership suggests that the key decisions are influenced by...

Champion Iron's (ASX:CIA) stock is up by a considerable 35% over the past three months. However, we wonder if the...

Some Kip McGrath Education Centres Limited ( ASX:KME ) shareholders may be a little concerned to see that insider Storm...

Insiders who bought Cryosite Limited ( ASX:CTE ) in the last 12 months may probably not pay attention to the stock's...

Key Insights The considerable ownership by individual investors in Prospect Resources indicates that they collectively...

Anyone interested in Imdex Limited ( ASX:IMD ) should probably be aware that the Independent Non-Executive Chairman...

Investors may wish to note that the Non Executive Independent Chairman of Beforepay Group Limited , Brian Hartzer...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

As the Australian market experiences a mixed performance with materials leading and IT and industrials lagging, investors are keenly observing sector shifts. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.

Immutep (ASX:IMM) has jumped onto investors radar after two meaningful updates: a lucrative licensing deal with Dr. Reddy’s for its cancer immunotherapy efti, and fresh Phase II breast cancer data reinforcing its development pathway. See our latest analysis for Immutep. The recent licensing deal and upbeat breast cancer data appear to have flipped sentiment, with a 1 month share price return of 25.49 percent and a 90 day share price return of 36.17 percent standing in contrast to a still...